Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

about

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q47221234-02CD3519-6389-46EC-A480-446813EE711E Q55283747-C27B857B-5C84-4AD9-B1C9-4BB04A4B3058

P2860

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

Item

http://www.wikidata.org/entity/Q38759420

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

@en

type

Item

label

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

@en

prefLabel

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

@en

P1476

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

@en

P2093

Anja Engelke

http://www.w3.org/2001/XMLSchema#string

Kirsten Fischer

http://www.w3.org/2001/XMLSchema#string

Natali Pflug

http://www.w3.org/2001/XMLSchema#string

Othman Al-Sawaf

http://www.w3.org/2001/XMLSchema#string

Valentin Goede

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Obinutuzumab in hematologic malignancies: lessons learned to date

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

The biology of CD20 and its potential as a target for mAb therapy

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

P304

295-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S104869

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hallek

Othman Al-Sawaf

Valentin Goede

P5008

ScienceSource

P577

2017-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28182141

http://www.w3.org/2001/XMLSchema#string

P921

chronic lymphocytic leukemia

globulins

monoclonal antibody

blood proteins

biomedical investigative technique

lymphocyte

P932

5279834

http://www.w3.org/2001/XMLSchema#string

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

about

P2860

P2860

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932